Age-dependent accumulation of genomic aberrations and deregulation of cell cycle and telomerase genes in metastatic neuroblastoma

International Journal of Cancer

Volumn 131, Issue 7, 2012, Pages 1591-1600

  Coco, Simona ^a   Theissen, Jessica ^b   Scaruffi, Paola ^a   Stigliani, Sara ^a   Moretti, Stefano ^c,d   Oberthuer, André ^b   Valdora, Francesca ^e   Fischer, Matthias ^b   Gallo, Fabio ^a   Hero, Barbara ^b   Bonassi, Stefano ^f   Berthold, Frank ^b   Tonini, Gian Paolo ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c CNRS   (France)

^d UNIVERSITÉ PARIS DAUPHINE   (France)

^e UNIVERSITY OF GENOA   (Italy)

^f IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

CGH; chromosome instability; metastatic tumor; microarray; neuroblastoma

Indexed keywords

RAS PROTEIN; RHO FACTOR; TELOMERASE;

AGE; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CELL ADHESION; CELL CYCLE; CELL CYCLE GENE; CELL MATURATION; CHILD; CHROMOSOME REARRANGEMENT; COHORT ANALYSIS; CONTROLLED STUDY; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; NEUROBLASTOMA; NUMERICAL CHROMOSOME ABERRATION; ONCOGENE; ONCOGENE MYCN; ONCOGENE RAS; PRESCHOOL CHILD; PRIORITY JOURNAL; RHO GENE; TELOMERASE GENE;

AGE FACTORS; CELL CYCLE; CHROMOSOME ABERRATIONS; DNA COPY NUMBER VARIATIONS; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; NEOPLASM METASTASIS; NEUROBLASTOMA; TELOMERASE;

EID: 84864494012     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27432     Document Type: Article

References (44)

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL,. Neuroblastoma. Lancet 2007; 369: 2106-20.
2. Brodeur GM,. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-16.
3. Breslow N, McCann B,. Statistical estimation of prognosis for children with neuroblastoma. Cancer Res 1971; 31: 2098-103.
4. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM,. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984; 224: 1121-4.
5. George RE, London WB, Cohn SL, Maris JM, Kretschmar C, Diller L, Brodeur GM, Castleberry RP, Look AT,. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 2005; 23: 6466-73.
6. De Bernardi B, Gerrard M, Boni L, Rubie H, Cañete A, Di Cataldo A, Castel V, Forjaz de Lacerda A, Ladenstein R, Ruud E, Brichard B, Couturier J, et al. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol 2009; 2: 1034-40.
7. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, et al. INRG Task Force. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009; 27: 298-303.
8. Maris JM, White PS, Beltinger CP, Sulman EP, Castleberry RP, Shuster JJ, Look AT, Brodeur GM,. Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res 1995; 55: 4664-9.
9. Caron H, Van Sluis P, De Kraker J, Bökkerink J, Egeler M, Laureys G, Slater R, Westerveld A, Voûte PA, Versteeg R,. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996; 334: 225-30.
10. Bown N, Cotterill S, Lastowska M, O'Neill S, Pearson AD, Plantaz D, Meddeb M, Danglot G, Brinkschmidt C, Christiansen H, Laureys G, Speleman F, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999; 340: 1954-61.
11. Spitz R, Hero B, Ernestus K, Berthold F,. Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma. Clin Cancer Res 2003; 9: 4835-40.
12. Attiyeh EF, London WB, Mossé YP, Wang Q, Winter C, Khazi D, McGrady PW, Seeger RC, Look AT, Shimada H, Brodeur GM, Cohn SL, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005; 353: 2243-53.
13. Spitz R, Hero B, Simon T, Berthold F,. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin Cancer Res 2006; 12: 3368-73.
14. Hiyama E, Hiyama K, Yamaoka H, Sueda T, Reynolds CP, Yokoyama T,. Expression profiling of favorable and unfavorable neuroblastomas. Pediatr Surg Int 2004; 20: 33-8.
15. Takita J, Ishii M, Tsutsumi S, Tanaka Y, Kato K, Toyoda Y, Hanada R, Yamamoto K, Hayashi Y, Aburatani H,. Gene expression profiling and identification of novel prognostic marker genes in neuroblastoma. Genes Chromosomes Cancer 2004; 40: 120-32.
16. Wei JS, Greer BT, Westermann F, Steinberg SM, Son CG, Chen QR, Whiteford CC, Bilke S, Krasnoselsky AL, Cenacchi N, Catchpoole D, Berthold F, et al. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res 2004; 64: 6883-91.
17. Ohira M, Oba S, Nakamura Y, Isogai E, Kaneko S, Nakagawa A, Hirata T, Kubo H, Goto T, Yamada S, Yoshida Y, Fuchioka M, et al. Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 2005; 7: 337-50.
18. Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J, Swerts K, Bravo S, Scaruffi P, Tonini GP, De Bernardi B, Noguera R, et al. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol 2009; 10: 663-7.
19. Oberthuer A, Hero B, Berthold F, Juraeva D, Faldum A, Kahlert Y, Asgharzadeh S, Seeger R, Scaruffi P, Tonini GP, Janoueix-Lerosey I, Delattre O, et al. Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol 2010; 28: 3506-15.
20. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B,. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999; 86: 349-63.
21. Spitz R, Oberthuer A, Zapatka M, Brors B, Hero B, Ernestus K, Oestreich J, Fischer M, Simon T, Berthold F,. Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes Chromosomes Cancer 2006; 45: 1130-42.
22. Fisher RA,. The logic of inductive inference. J R Stat Soc Ser A 1935; 98: 39-54.
23. Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, Ernestus K, Konig R, Haas S, Eils R, Schwab M, Brors B, et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006; 24: 5070-8.
24. Smyth GK,. Limma: linear models for microarray data. In:, Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, eds. Bioinformatics and computational biology solutions using R and bioconductor, R. New York: Springer, 2005. 397-420.
25. Smyth GK, Speed TP,. Normalization of cDNA microarray data. Methods 2003; 31: 265-73.
26. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J, Speed TP,. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002; 30: e15.
27. Yang YH, Thorne NP,. Normalization for two-color cDNA microarray data. In:, Goldstein DR, ed. Science and statistics: a Festschrift for Terry speed. IMS Lect Notes Monogr Ser 2003; 40: 403-18.
28. Storey JD, Tibshirani R,. SAM thresholding and false discovery rates for detecting differential gene expression in DNA microarray. In:, Parmigiani G, Garrett ES, Irizarry RA, Zeger SL, eds. The analysis of gene expression data: methods and software. New York: Springer, 2003. 272-90.
29. Cawthon RM,. Telomere measurement by quantitative PCR. Nucleic Acids Res 2002; 30: e47.
30. Albino D, Scaruffi P, Moretti S, Coco S, Truini M, Di Cristofano C, Cavazzana A, Stigliani S, Bonassi S, Tonini GP,. Identification of low intratumoral gene expression heterogeneity in neuroblastic tumors by genome-wide expression analysis and game theory. Cancer 2008; 113: 1412-22.
31. Scaruffi P, Coco S, Cifuentes F, Albino D, Nair M, Defferrari R, Mazzocco K, Tonini GP,. Identification and characterization of DNA imbalances in neuroblastoma by high-resolution oligonucleotide array comparative genomic hybridization. Cancer Genet Cytogenet 2007; 177: 20-9.
32. Bénard J, Raguénez G, Kauffmann A, Valent A, Ripoche H, Joulin V, Job B, Danglot G, Cantais S, Robert T, Terrier-Lacombe MJ, Chassevent A, et al. MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S. Mol Oncol 2008; 2: 261-71.
33. Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, Vermeulen J, Couturier J, Peuchmaur M, Valent A, Plantaz D, Rubie H, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009; 27: 1026-33.
34. Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, Klijanienko J, Couturier J, Pierron G, Mosseri V, Valent A, Auger N, Plantaz D, Rubie H, Valteau-Couanet D, et al. Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol 2010; 28: 3122-30.
35. Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B,. Mutations of mitotic checkpoint genes in human cancers. Nature 1999; 392: 300-3.
36. Carén H, Kryh H, Nethander M, Sjöberg R-M, Träger C, Nilsson S, Abrahamsson J, Kogner P, Martinsson T,. High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci USA 2010; 107: 4323-28.
37. Colicelli J,. Human RAS superfamily proteins and related GTPases. Sci STKE 2004; 250: RE13.
38. Park HT, Wu J, Rao Y,. Molecular control of neuronal migration. Bioessays 2002; 24: 821-7.
39. Sandell LL, Zakian VA,. Loss of a yeast telomere: arrest, recovery, and chromosome loss. Cell 1993; 75: 729-39.
40. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW,. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-15.
41. Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW,. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1995; 1: 249-55.
42. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z,. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006; 38: 1043-8.
43. Lodygin D, Hermeking H,. The role of epigenetic inactivation of 14-3-3sigma in human cancer. Cell Res 2005; 15: 237-46.
44. Putnam CD, Hayes TK, Kolodner RD,. Post-replication repair suppresses duplication-mediated genome instability. PLoS Genet 2010; 6: 1000933.